Privia Health Group Inc
NASDAQ:PRVA

Watchlist Manager
Privia Health Group Inc Logo
Privia Health Group Inc
NASDAQ:PRVA
Watchlist
Price: 23.43 USD 0.3% Market Closed
Market Cap: $3B

Wall St Price Targets

PRVA Price Targets Summary
Privia Health Group Inc

Wall Street analysts forecast PRVA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PRVA is 32.07 USD with a low forecast of 24.24 USD and a high forecast of 42 USD.

Lowest Forecast
Price Target
24.24 USD
3% Upside
Average Forecast
Price Target
32.07 USD
37% Upside
Highest Forecast
Price Target
42 USD
79% Upside
Privia Health Group Inc Competitors:
Price Targets
VNET
Vianet Group PLC
217% Upside
YUMC
Yum China Holdings Inc
39% Upside

Revenue
Forecast

18% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-42%
Average Miss
18% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-42%
Average Miss

Over the last 6 years, the compound annual growth rate for Revenue has been 18%. The projected CAGR for the next 3 years is 12%.

Gross Profit
Forecast

20% / Year
Past Growth
46% / Year
Estimated Growth
Estimates Accuracy
-40%
Average Miss
20% / Year
Past Growth
46% / Year
Estimated Growth
Estimates Accuracy
-40%
Average Miss

Over the last 6 years, the compound annual growth rate for Gross Profit has been 20%. The projected CAGR for the next 2 years is 46%.

Operating Income
Forecast

13% / Year
Past Growth
52% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss
13% / Year
Past Growth
52% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Over the last 6 years, the compound annual growth rate for Operating Income has been 13%. The projected CAGR for the next 3 years is 52%.

Pre-Tax Income
Forecast

30% / Year
Past Growth
47% / Year
Estimated Growth
Estimates Accuracy
-24%
Average Miss
30% / Year
Past Growth
47% / Year
Estimated Growth
Estimates Accuracy
-24%
Average Miss

Over the last 6 years, the compound annual growth rate for Pre-Tax Income has been 30%. The projected CAGR for the next 3 years is 47%.

Net Income
Forecast

19% / Year
Past Growth
57% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss
19% / Year
Past Growth
57% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss

Over the last 6 years, the compound annual growth rate for Net Income has been 19%. The projected CAGR for the next 3 years is 57%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is PRVA's stock price target?
Price Target
32.07 USD

According to Wall Street analysts, the average 1-year price target for PRVA is 32.07 USD with a low forecast of 24.24 USD and a high forecast of 42 USD.

What is the Revenue forecast for Privia Health Group Inc?
Projected CAGR
12%

Over the last 6 years, the compound annual growth rate for Revenue has been 18%. The projected CAGR for the next 3 years is 12%.

What is the Gross Profit forecast for Privia Health Group Inc?
Projected CAGR
46%

Over the last 6 years, the compound annual growth rate for Gross Profit has been 20%. The projected CAGR for the next 2 years is 46%.

What is the Operating Income forecast for Privia Health Group Inc?
Projected CAGR
52%

Over the last 6 years, the compound annual growth rate for Operating Income has been 13%. The projected CAGR for the next 3 years is 52%.

What is the Pre-Tax Income forecast for Privia Health Group Inc?
Projected CAGR
47%

Over the last 6 years, the compound annual growth rate for Pre-Tax Income has been 30%. The projected CAGR for the next 3 years is 47%.

What is the Net Income forecast for Privia Health Group Inc?
Projected CAGR
57%

Over the last 6 years, the compound annual growth rate for Net Income has been 19%. The projected CAGR for the next 3 years is 57%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett